Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Experien Group, GE Healthcare, Haliodx, Mindmed, Modivcare, Northstar Medical Radioisotopes, Resolve Bioscience, Sorrento Therapeutics, Veracyte, Veranex, VRI Intermediate Holdings, Zeiss.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbvie, Ancilia, Burning, China Grand Pharmaceutical, Etherna, GT, Impact, Innocan, Insilico, Sanotize, Takeda, Westlake.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 89bio, Biogen, Biophytis, Cytokinetics, Flugen, Humanigen, Ionis, Moderna, Novartis, Prometheus, Servier, Zentalis.
The world has been running an ultramarathon since the COVID-19 pandemic began, but despite the ups and downs of cases and deaths, the wins and losses of clinical efforts, every day is another step forward toward herd immunity and the finish line.
PARIS – At some point, scientists reported, it may be possible to quarantine viruses rather than humans. For the last two years, European research consortium Virofight has been working on a form of nanotechnology intended to neutralize viruses such as SARS-CoV-2, HIV, influenza and hepatitis viruses.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Blackford, Breathtek, Evonik, Jenacell, Meridian Bioscience, Paramit, Provista Diagnostics, Sense Neuro Diagnostics, Sensyne, The Tecan Group, Todos Medical.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acurx, Affimed, Amount, Arcturus, Autolus, Bausch, Carrick, Johnson & Johnson, Moderna, Oligomerix, Polyphor, Roche, Seqirus.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alector, Astrazeneca, Beigene, Biogen, Cyclo, Enyo, Lilly, Optinose, RDIF, Vaxart.
Rapid changes, a traditionally conservative approach and a chronic lack of regulatory transparency could undo a lot of the progress that Japan has made in the past few years to speed up approvals and all but eliminate a punishing drug lag that, for decades, held back the development of the country’s biopharma sector.
RSS
